Drug Search Results
More Filters [+]

Nilutamide

Alternative Names: nilutamide, nilandron
Latest Update: 2024-10-17
Latest Update Note: Clinical Trial Update

Product Description

Nilutamide is a nonsteroidal antiandrogen with affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid receptors. Consequently, nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and cancerous prostatic tissue.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8453188/)

Mechanisms of Action: AR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intramuscular,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Chile | Colombia | France | India | Mexico | Netherlands | New Zealand | Pakistan | Peru | Portugal | Slovenia | Sweden | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nilutamide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title